Log in

NASDAQ:SNNASienna Biopharmaceuticals Stock Price, Forecast & News

$0.14
0.00 (0.00 %)
(As of 12/16/2019)
Add
Compare
Today's Range
$0.11
Now: $0.14
$0.17
50-Day Range
$0.14
MA: $0.14
$0.14
52-Week Range
$0.06
Now: $0.14
$3.80
Volume13.32 million shs
Average Volume3.85 million shs
Market Capitalization$4.20 million
P/E RatioN/A
Dividend YieldN/A
Beta2.67
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNNA
CUSIPN/A
Phone818-629-2256

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.27 per share

Profitability

Net Income$-73,470,000.00

Miscellaneous

Employees39
Market Cap$4.20 million
Next Earnings DateN/A
OptionableNot Optionable
$0.14
0.00 (0.00 %)
(As of 12/16/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive SNNA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sienna Biopharmaceuticals (NASDAQ:SNNA) Frequently Asked Questions

How has Sienna Biopharmaceuticals' stock price been impacted by COVID-19?

Sienna Biopharmaceuticals' stock was trading at $0.1358 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SNNA shares have increased by 0.0% and is now trading at $0.1358.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Sienna Biopharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sienna Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Sienna Biopharmaceuticals
.

How were Sienna Biopharmaceuticals' earnings last quarter?

Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) posted its quarterly earnings data on Thursday, March, 14th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.83) by $0.10.
View Sienna Biopharmaceuticals' earnings history
.

What price target have analysts set for SNNA?

1 brokerages have issued 1 year target prices for Sienna Biopharmaceuticals' stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate Sienna Biopharmaceuticals' stock price to reach $3.00 in the next year. This suggests a possible upside of 2,109.1% from the stock's current price.
View analysts' price targets for Sienna Biopharmaceuticals
.

Has Sienna Biopharmaceuticals been receiving favorable news coverage?

Media headlines about SNNA stock have trended neutral this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sienna Biopharmaceuticals earned a media sentiment score of 0.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Sienna Biopharmaceuticals
.

Who are some of Sienna Biopharmaceuticals' key competitors?

What other stocks do shareholders of Sienna Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sienna Biopharmaceuticals investors own include SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Selecta Biosciences (SELB), Spectrum Pharmaceuticals (SPPI), Viking Therapeutics (VKTX), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Novavax (NVAX), Protalix Biotherapeutics (PLX) and Ring Energy (REI).

Who are Sienna Biopharmaceuticals' key executives?

Sienna Biopharmaceuticals' management team includes the following people:
  • Dr. Frederick C. Beddingfield III, CEO, Pres & Director (Age 54)
  • Mr. Timothy K. Andrews Esq., Gen. Counsel & Corp. Sec. (Age 40)
  • Mr. Alexander Azoy, CFO & Controller (Age 43)
  • Mr. Majed Kheir, VP of Operations (Age 41)
  • Dr. Silvio Traversa BSc Ph.D., Chief Scientific Officer (Age 49)

When did Sienna Biopharmaceuticals IPO?

(SNNA) raised $64 million in an initial public offering (IPO) on Thursday, July 27th 2017. The company issued 4,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets served as the underwriters for the IPO.

What is Sienna Biopharmaceuticals' stock symbol?

Sienna Biopharmaceuticals trades on the NASDAQ under the ticker symbol "SNNA."

How do I buy shares of Sienna Biopharmaceuticals?

Shares of SNNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sienna Biopharmaceuticals' stock price today?

One share of SNNA stock can currently be purchased for approximately $0.14.

How big of a company is Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals has a market capitalization of $4.20 million. The company earns $-73,470,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Sienna Biopharmaceuticals employs 39 workers across the globe.

What is Sienna Biopharmaceuticals' official website?

The official website for Sienna Biopharmaceuticals is www.siennabio.com.

How can I contact Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals' mailing address is 30699 Russell Ranch Road Suite 140, Westlake Village CA, 91362. The company can be reached via phone at 818-629-2256 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.